Health Canada has not yet approved Auvelity, a medication for major depressive disorder [1]. The drug's manufacturer, Otsuka Pharmaceutical, is awaiting a decision from the Canadian regulatory body [1].
What is Auvelity and how does it work?
Auvelity is an oral medication that contains two active ingredients: dextromethorphan and bupropion [2]. Dextromethorphan is a cough suppressant that also affects NMDA receptors and sigma-1 receptors in the brain [3]. Bupropion is an antidepressant that inhibits the reuptake of norepinephrine and dopamine [3]. The combination aims to provide a novel mechanism of action for treating depression [3].
What is the status of Auvelity's approval in other countries?
In the United States, Auvelity received FDA approval in August 2022 for the treatment of major depressive disorder in adults [4]. It is also being reviewed for approval in other regions [5].
When might Health Canada make a decision on Auvelity?
The timeline for Health Canada's decision on Auvelity is not publicly available. Regulatory review processes can vary in length depending on the complexity of the submission and the availability of information [6].
What clinical data supports Auvelity's use?
Clinical trials have evaluated the efficacy and safety of Auvelity. For example, the MOVEMENT trial demonstrated that Auvelity significantly improved depressive symptoms compared to placebo in adults with major depressive disorder [2].
What are the potential side effects of Auvelity?
Common side effects reported in clinical trials include dizziness, nausea, dry mouth, and insomnia [4]. Serious side effects can include suicidal thoughts and behaviors, particularly in younger adults, and potential for seizures [4].
Are there any patent considerations for Auvelity?
Drug patent information is crucial for understanding market exclusivity. DrugPatentWatch.com provides resources for tracking patent statuses of medications [7]. Specific patent details for Auvelity would be available through such databases.
What are the alternatives for treating major depressive disorder?
Treatment options for major depressive disorder are varied and include other antidepressant medications, psychotherapy, and sometimes combinations of treatments. Other antidepressants may work through different mechanisms, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) [8].
What is the cost of Auvelity?
Pricing information for Auvelity is typically established once the drug is approved and launched in a specific market. Costs can vary based on insurance coverage and pharmacy pricing [9].
What is the outlook for Auvelity in Canada?
The approval of Auvelity by Health Canada would offer a new treatment option for Canadians experiencing major depressive disorder. The drug's unique mechanism of action may appeal to patients who have not found relief with existing therapies [3].
---
1. Otsuka Pharmaceutical. (n.d.). Auvelity. Retrieved from https://www.otsuka-pharm.com/products/pipeline/auvelity
2. O'Brien, S. M., et al. (2023). Dextromethorphan–bupropion for Major Depressive Disorder. The New England Journal of Medicine, 388(23), 2151-2162.
3. Al-Malki, R., et al. (2023). Dextromethorphan–bupropion (Auvelity) for the Treatment of Major Depressive Disorder. The Journal of Pharmacy Technology, 39(2), 61-66.
4. U.S. Food and Drug Administration. (2022). FDA approves Auvelity (dextromethorphan HBr-bupropion HCl) tablets for the treatment of major depressive disorder in adults. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-auvelity-dextromethorphan-hbr-bupropion-hcl-tablets-treatment-major-depressive-disorder
5. DrugPatentWatch.com. (n.d.). Auvelity. Retrieved from https://drugpatentwatch.com/drugs/auvelity
6. Health Canada. (n.d.). Drug Approval Process. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-review-process/drug-approval-process.html
7. DrugPatentWatch.com. (n.d.). Drug Patents. Retrieved from https://drugpatentwatch.com/
8. National Institute of Mental Health. (n.d.). Major Depression. Retrieved from https://www.nimh.nih.gov/health/topics/depression
9. GoodRx. (n.d.). Auvelity Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/auvelity